Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-896P is a pseudogene member of the U6 small nuclear RNA gene family. Pseudogenes of U6 snRNA are produced through retrotransposition mechanisms, creating nonfunctional genomic copies of the original functional snRNA gene[2]. While canonical U6 snRNA is an essential RNA molecule that forms the core of the spliceosome and catalyzes pre-mRNA splicing, RNU6-896P itself is noncoding and does not participate in spliceosomal activity or cellular regulation[2][3][4]. The presence of such pseudogenes is common in vertebrate genomes and reflects evolutionary processes and the dynamics of retrotransposon-mediated gene duplication[2][3]. There is no evidence of RNU6-896P acting as a therapeutic target, nor any association with drugs or disease beyond its general role as a genomic marker of L1 retrotransposon activity[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 896, pseudogene (RNU6-896P).